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ATTENTION has been drawn to the possible adverse effects of anticonvulsant
drugs on bone metabolism by a number of reports in recent years (Dent et al,
1970; Richens and Rowe, 1970; Hunter et al, 1971; Lifshitz and Maclaren, 1973;
Stamp, 1974; British Medical Journal, 1976). The aim of the present study was to
investigate this potentially serious side-effect of anticonvulsant therapy in the
setting of Muckamore Abbey, a mental subnormality hospital in Northern Ireland.
POPULATION ON ANTICONVULSANT THERAPY
The hospital population consists of 850 patients of all grades of subnormality
and of all ages, many of whom have been institutionalised for prolonged periods.
They are housed in 20 villas according to age, sex, severity of retardation and
presence of physical handicaps. An initial survey of the whole hospital revealed
316 patients on long-term (six months or more) anticonvulsant therapy. The
present study comprised 292 (92 per cent) of these patients from whom it was
possible to obtain a blood specimen. This was a therapeutic investigation of
patients receiving usual hospital therapy who might be at risk from a recognised
side-effects of the drug (Hahn, Hendin et al, 1972). Nevertheless, there were some
patients among the total of 316 who refused to have the venepuncture and these
were not assessed further.
There were 149 males and 143 females ranging in age from 3 to 81 years.
The group included mentally subnormal patients suffering from a variety of
associated and coincidental physical conditions, but excluding known disorders
afiecting bone metabolism. Nine patients were not suffering from any physical
handicap. As would be expected with a group of patients receiving anticonvulsants,
the majority were epileptic; 18 (6 per cent) were being treated with drugs such as
sulthiame (Ospolot) and carbamazepine (Tegretol) to control behavioural prob-
lems. Over half had had at least one fit during the preceding year. Two hundred
and twenty-six (77 per cent) had been on continuous anticonvulsant therapy for
over five years and took a wide range of other drugs. All were Caucasian and
domiciled in Northern Ireland. They were being offered an adequate diet but were
not routinely given vitamin supplements. The amount of exposure to direct
sunlight was dependent on the patient's degree of mobility. The majority were
ambulant and able to get outside in fine weather, but a few of the most severely
handicapped were confined to their villas.
63Initial survey
Between October 1976 and January 1977, venous blood samples were obtained
from the 292 patients, venous compression being used if necessary. The concen-
trations of calcium, phosphate and alkaline phosphatase in the serum were deter-
mined as follows: calcium and phosphate were measured on the Gilford 3500
analyser, using the methyl-thymol-blue method for calcium, and molybdate with
reducing reagents for phosphate; alkaline phosphatase was measured in the
Vickers D300 apparatus, with phenolphthalein monophosphate. The "usual
hospital range" in a general hospital population using these techniques is: calcium
2.20 to 2.65 mmol/l; phosphate 0.8 to 1.5 mmol/l; and alkaline phosphatase 21
to 91 U/I (Belfast City Hospital Clinical Chemistry Department). The serum
alkaline phosphatase level is more age-dependent than either the calcium or
phosphate. The upper limit of normal values in health can extend to 200 U/i in
childhood, whereas it should not exceed 91 U/I in adults. As the age distribution
of the present study is wide, the data is presented as a frequency distribution for
the actual population rather than applying correction factors for age or other
possible variables. The laboratory upper limit for a usual value in health for serum
alkaline phosphatase is thus expressed as a range of 91-200 U/I (Fig. 1).
A further blood sample was obtained (second survey) from 105 of the 133
patients in whom results of the first sample were abnormal. The two results for
each individual who had a second test were averaged. There were 10 of these
patients whose average calcium was less than 2.0 mmol/l. These 10 had further
plasma samples analysed for 25-hydroxycholecalciferol and parathormone levels.
Plasma 25-hydroxycholecalciferol and parathormone determinations were carried
out by the Supraregional Endocrine Assay Service, using standard radioimmuno-
assay techniques.
Radiographic survey
Fifty-nine of the 113 patients with calcium values of less than 2.2 mmol/l,
phosphate less than 0.8 mmol/1 or alkaline phosphatase greater than 200 U/1,
had radiographs of wrists and forearms. This was standardised as far as possible
and most patients were exposed to 45 kv and 80 ma for 0.16 seconds. A few
patients had less or more according to their build. Assessment of the radiographs
was carried out by one of us (EMMcI) without knowledge of the clinical or bio-
chemical findings. A subjective classification into normal, osteoporotic and osteo-
malacic was made and the transmitted light value measured.
Pharmacological survey
A "drug score" was calculated for each patient, using the technique of Richens
and Rowe (1970). This derives a numerical score for the total daily dose of certain
anticonvulsant drugs. A dose of 50 mg phenytoin or 30 mg phenobarbitone scored
1 unit and 250 mg primidone scored 1.5 units. A total daily score for each patient
was calculated.
64Control studies
Thirty-two patients were examined. These consisted of two or three patients
from each ward in the same hospital who had been receiving no drug therapy for
at least 3 months. Blood samples were obtained in the same way and serum
concentrations of calcium, phosphate and alkaline phosphatase were measured.
RESULTS
Initial survey
The distribution of serum calcium, phosphate and alkaline phosphatase in the
292 patients is shown in Figs. 1, 2 and 3. The mean serum calcium was 2.26
(standard deviation 0.09) mmol/l, mean serum phosphate 1.09 (S.D. 0.31)
mmol/I and the mean serum alkaline phosphatase 91.8 (S.D. 61.0 U/1). By com-
parison with the usual hospital range it is clear that there is a shift to the left of
the serum calcium values for the patients taking anticonvulsant drugs; 60 (21 per
cent) were below 2.20 mmol/1 and none were above the upper limit. For serum
phosphate 17 (6 per cent) were below 0.8 mmol/I and for alkaline phosphatase
14 (5 per cent) were above 200 U/1.
80 s
60
z
P-
t 40
0
z
20-
MEAN 2. 26
SD 0.09
- .-_- SEM 0.01
o -km=
1.9 2.0 2.10 2.20
CALCIUM mmol/I f
2.30 2.40 2.50 2.60
USUAL RANGE
FIG. 1: Frequency distributions oj serum calcium (mmoi/l) in
the 292 patients receiving long-term anticonvulsant therapy
(initial survey).
65
a 5
=4
L1.0 1.2 1.4 1.6 1.8 2.0
USUAL RANGE
PHOSPHATE mmol/I
FIG. 2: Frequency distributions of serum phosphate (mmol/l) in
the 292 patients receiving long-term anticonvulsane therapy
(initial survey).
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FIG. 3: Frequency distributions of alkaline phosphatase (U/l) in
the 292 patients receiving long-term anticonvulsant therapy
(initial survey).
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I I I 4 aThe 32 control patients all had serum calcium within the quoted "usual
hospital range" of 2.20 to 2.65 mmol/l; four control patients had a serum phos-
phate below and two above the usual hospital range of 0.8 to 1.6 mmol/l; none
had an alkaline phosphatase above 200 U/1.
The relationship between serum calcium and phosphate in the 292 patients
is shown in Fig. 4 (r=0.10). Six patients (2 per cent) had low values of both
calcium and phosphate, but none of these had an alkaline phosphatase above
90 U/1.
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FIG. 4: The relation between serum calcium and phosphate in the
292 patients receiving long-term anticonvulsani therapy
(r=O.I). Six patients had values for both calcium and
phosphate below the usual hospital ranges (dotted lines).
Radiographic survey
Thirty-six of the radiographs were subjectively assessed as normal, fifteen as
osteoporotic and eight as osteomalacic. Table 1 shows the biochemical and trans-
mitted light values in these three groups. There was a tendency for those judged
osteoporotic to be older and those judgd osteomalacic to be younger than the
usual group. The mean transmitted light value was lowest for the osteoporotic
group and intermediate for the osteomalacic group, confirming the subjective
diagnosis. There was no difference in the mean blood calcium values. The blood
phosphate was lowest in the osteoporotic group and the alkaline phosphatase
highest in the osteomalacic group (although these were considerably younger).
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ATABLE 1: RADIOLOGICAL SURVEY-59 PATIENTS
(Values are means ± standard errors of the mean)
Subjective Mean Transmitted Alkaline
Radiological Age Light Value Calcium Phosphate Phosphatase
Diagnosis No. (arbitrary units) mmol/l mmol/l U/i
Normal 36 29 6.70 2.19 1.04 99
±0.14 +0.02 ±0.05 +11
Osteoporosis 15 51 5.80 2.14 0.87 93
±0.18 +0.03 +0.05 ±10
Osteomalacia 8 16 6.20 2.14 1.19 315
+0.40 +0.05 ±0.10 +45
Pharmacological survey
The drug score (for the day on which the blood sample was obtained) for the
292 patients in the initial survey is shown in relation to the serum calcium in Fig.
5. The correlation coefficient r was -0.25, and there was a general trend for those
patients with the lowest calcium values to have a higher drug score.
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FIG. 5: The anticonvulsant drug score (see text) related to the
serum calcium value on the sane day in the 292 patients
receiving long-term anticonvulsant therapy (r = -025).
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.Table 2 shows the frequency of hypocalcaemia in patients receiving the three
most commonly administered anticonvulsant drugs (phenobarbitone, phenytoin
or primidone). The greatest incidence of hypocalcaemia was found in patients
taking primidone with or without other drugs (Table 2). However, most of the
patients were on more than one of these drugs, so these data do not necessarily
allow individual comparison of the effect of one or other drug alone. When two
or three of these drugs were taken in combination, 82 patients (32 per cent) had
a low serum calcium; when only one drug was taken, 142 patients (21 per cent)
had a low serum calcium. For the 68 patients who received none of these three
drugs, only four (6 per cent) had a low serum calcium.
TABLE 2: RELATION BETWEEN SERUM CALCIUM AND INDIVIDUAL
ANTICONVULSANT DRUGS
(Many patients were receiving more than one drug concurrently)
Patients with Mean serum
serum calcium calcium Mean daily
Drug Patients <2.20mmol/l mmol/l dose mg
Phenobarbitone 141 31 (22%) 2.29 95
Phenytoin 120 36 (30%) 2.25 205
Primidone 60 22 (37%) 2.23 640
Parathormone and 25-Hydroxycholecalciferol data
Data for a third blood sample on ten patients found after the second survey
with mean serum calcium below 2.Ommol/1 are shown in Table 3. The serum
calcium was still below 2.1mmol/1 in all of the patients. Serum parathormone
values were elevated above the upper limit or normal (0.73microg/1) in 3 and
serum 25-hydroxycholecalciferol values were well below the normal range (3.5
to 30microg/l) in all of these patients.
TABLE 3: SERUM VALUES FOR A THIRD BLOOD SPECIMEN IN
SEVERELY HYPOCALCAEMIC PATIENTS
1-4~~~~~~~~~~~~~~~~
AS 14 F 2.09 1.20 187 1.1 0.35 3.0
JMCC 14 F 2.01 0.90 480 1.9 1.20 4.5
BMcG 15 F 2.06 0.80 430 0.8 1.20 10.0
BM 16 M 2.09 1.10 476 0.8 0.66 3.0
MM 19 F 2.04 1.10 289 1.4 0.96 2.3
JF 30 M 2.09 1.00 39 2.6 0.20 3.0
EMcC 36 F 1.97 1.20 104 0.8 0.44 6.0
WMCC 46 M 1.99 0.90 87 0.8 0.34 9.0
TH 46 F 2.08 0.70 90 0.8 0.29 5.5
CG 81 F 2.02 0.60 90 0.8 0.44 6.6
Mean 32 2.03 0.95 176 1.2 0.62 6.3
SEM +8 +0.07 ±0.07 +56 +0.2 +0.12 +0.8DISCUSSION
Mechanism by which anticonvulsant drugs alter calcium metabolism
During chronic therapy with certain drugs a gradual decline in the plasma level
of the drug may be observed. This results from the ability of some compounds
to stimulate their own metabolism by inducing an increased production of liver
microsomal enzymes. There are various enzyme systems in the liver and some
have an effect, not only on the drugs which induce them, but also on normal
body constituents such as the steroid hormones (Kuntzman, 1969). Cholecalciferol
(Vitamin D3) is chemically similar in structure to certain steroids and there is
strong evidence that the increased incidence of osteomalacia observed in patients
on anticonvulsant therapy may be the result of an accelerated conversion of
cholecalciferol and its active metabolite 25-hydroxycholecalciferol to inactive
metabolites by drug-induced liver microsomal enzymes (Hahn, Birge et al, 1972).
Significance of biochemical findings
The findings in this study are consistent with those of other studies as regards
the prevalence of low serum calcium and raised alkaline phosphatase. Richens
and Rowe (1970) studied 160 patients aged 16-70 years in an epileptic centre and
found a subnormal calcium in 22.5 per cent and raised alkaline phosphatase
activity in 29 per cent. Hunter et al (1971) studied 105 children in a residential
school and found low calcium in 30 per cent and raised alkaline phosphatase
activity in 24 per cent. The other authors did not examine serum phosphate (and
this was below 0.8mmol/l in only 6 per cent of patients in the present study).
Albright and Reifenstein (1948) graded osteomalacia into four stages. Thus,
about 20 per cent of the Muckamore Abbey population on anticonvulsant drugs
cou!d be said to have at least biochemical rickets (Stage I, with persistently low
calcium and/or phosphate and normal alkaline phosphatase and Stage II, with
elevated alkaline phosphatase). Of these, eight patients (1.6 per cent) had
unequivocal radiological changes (Stage III). There were no patients with the
overt full clinical syndrome (Stage IV, with myopathy, painful bones and skeletal
deformities).
Hypocalcaemia, if not compensated by secondary hyperparathyroidism, may
lead to tetany, which can progress to convulsions and eventually to intellectual
deterioration and dementia. These features in a mentally subnormal epileptic
population might not arouse clinical interest and could te overlooked. This would
be the more so because mentally subnormal (or mentally ill) patients may not
complain of early symptoms. Vague bone pains, one of the most characteristic
features of osteomalacia, might easily be labelled "neurotic" and obscure the
correct diagnosis. Stamp (1974) has reported cases in which a vicious circle was
set up, epilepsy treated with anticonvulsants producing hypocalcaemia, leading to
an increased frequency of fits, leading to an increase in anticonvulsant therapy,
in turn aggravating the hypocalcaemia. Secondary hyperparathyroidism in re-
sponse to chronic hypocalcaemia would be expected to protect these patients from
tetany at the expense of further skeletal decalcification.
70The fact that hypocalcaemia in patients on anticonvulsant therapy is associated
ated with low serum 25-hydroxycholecalciferol is now well established (Hahn,
Hendin et al, 1972; Stamp et al, 1972). This is supported by the consistently low
levels found in the ten hypoglycaemic patients in this study. The response of the
parathyroid glands to drug-induced osteomalacia has also been the subject of
investigation (Greenlaw et al, 1972) and the raised parathormone level in three
of the ten hypocalcaemic patients shows that secondary hyperparathyroidism has
occurred; why this is not so in all the cases is not clear.
Radiological assessment
The radiographic survey did not suggest that the techniques for identifying
demineralisation were sensitive enough to be used for routine screening of patients
at possible risk, although it was helpful in diagnosis when the biochemical results
were suggestive. Whether long-term radiological follow-up of those patients with
decalcified bones would be justified is also doubtful, and it is probable that simple
biochemical measurements will be sufficient for this purpose. All methods of
measurement of bone density by X-rays other than by microradiography or com-
puterised axial tomography (E.M.I. scans) are suspect. Even sophisticated methods
involving cortico/medullary ratios, or water-bath radiography using aluminium
or calcium hydroxyapatite step wedges have been shown to be erroneous. It is
also relevant that osteoporosis and osteomalacia can affect the axial skeleton
markedly with little subjective or objective change in the peripheral bones and
therefore the hand and wrist is not an ideal area to study.
The prevalence of biochemical and radiographic osteomalacia in this mentally-
retarded institutionalised population of all ages points to the need for administra-
tion of Vitamin D supplements (Hunter et al, 1971; Hahn, Hendin et al, 1972;
Maclaren and Lifshitz, 1973). There is still uncertainty as to the correct thera-
peutic dose of Vitamin D (or one of its more active metabolites) in this situation,
for there is evidence of considerable resistance to the usual preparation of
cholecalciferol (Vitamin D3) and of rapid biochemical improvement with small
doses of 25-hydroxycholecalciferol. As this latter preparation or the close deriva-
tive 1-alpha hydroxycholecalciferol is now available for clinical use, it would seem
important to study the effect of routine supplementation with a small dose of one
of these substances in a population at risk.
SUMMARY
A biochemical and radiographic survey of 292 patients who were receiving
long-term anticonvulsant therapy at the Muckamore Abbey Hospital has been
carried out. Twenty-one per cent of these patients had biochemical hypocalcaemia.
Only six patients had both serum calcium less than 2.20mmol/1 and phosphate
less than 0.8mmol/l.
Radiographs of the forearms and wrists were less sensitive in demonstrating
minor abnormalities. Fifteen were assessed as osteoporotic and eight as osteo-
malacic. There was a greater prevalence of hypocalcaemia with primidone than
with phenytoin or phenobarbitone and combinations of these drugs had an addi-
71tive effect. Among the ten most severely hypocalcaemic patients, all had very low
values of 25-hydroxycholecalciferol and three had clear evidence of secondary
hyperparathyroidism.
This study supports others that there is a definite risk of chronic decalcifying
bone disease among instutionalised patients on long-term anticonvulsant therapy.
None of these patients showed any overt clinical sign usually associated with
chronic bone disease.
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